Total and bone-specific alkaline phosphatases in haemodialysis patients with chronic liver disease

Clinical Biochemistry

Volumn 45, Issue 6, 2012, Pages 436-439

  Jean, Guillaume ^a   Souberbielle, Jean Claude ^b   Zaoui, Eric ^c   Lorriaux, Christie ^a   Mayor, Brice ^a   Hurot, Jean Marc ^a   Deleaval, Patrick ^a   Chazot, Charles ^a  

^a Nephrocare   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c UNILAB Laboratoire du Parc   (France)

Author keywords

Alkaline phosphatase; Bone markers; Haemodialysis; Liver disease; Parathyroid hormone

Indexed keywords

ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; PARATHYROID HORMONE;

AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE TURNOVER; CENTRAL VENOUS CATHETER; CHRONIC LIVER DISEASE; DIABETES MELLITUS; FEMALE; HEART DISEASE; HEMODIALYSIS PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; VITAMIN SUPPLEMENTATION;

AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE AND BONES; CASE-CONTROL STUDIES; CHRONIC DISEASE; FEMALE; HUMANS; LINEAR MODELS; LIVER DISEASES; MALE; MIDDLE AGED; PARATHYROID HORMONE; RENAL DIALYSIS;

EID: 84858440422     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.01.018     Document Type: Article

References (32)

1. KDIGO C-M Work Group KDIGO Clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone disorder (CKD-MBD). Kidney Int 2009, 76(Suppl 113):S1-S130.
2. Chertow G.M., Raggi P., Chasan-Taber S., Bommer J., Holzer H., Burke S.K. Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 2004, 19(6):1489-1496.
3. Andress D.L. Adynamic bone in patients with chronic kidney disease. Kidney Int 2008, 73(12):1345-1354.
4. Neves K.R., Graciolli F.G., dos Reis L.M., Graciolli R.G., Neves C.L., Magalhaes A.O., et al. Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int 2007, 71(12):1262-1270.
5. Danese M.D., Kim J., Doan Q.V., Dylan M., Griffiths R., Chertow G.M. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 2006, 47(1):149-156.
6. Brandi L., Daugaard H., Nielsen P.K., Jensen L.T., Egsmose C., Olgaard K. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis. Nephron 1996, 74(1):89-103.
7. Jean G., Chazot C., Charra B. 12 months cinacalcet therapy in hemodialysis patients with secondary hyperparathyroidism: effect on bone markers. Clin Nephrol 2007, 68(1):63-64.
8. Qi Q., Monier-Faugere M.C., Geng Z., Malluche H.H. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis 1995, 26(4):622-631.
9. Barreto F.C., Barreto D.V., Moyses R.M., Neves K.R., Canziani M.E., Draibe S.A., et al. K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int 2008, 73(6):771-777.
10. Slatopolsky E., Finch J., Clay P., Martin D., Sicard G., Singer G., et al. A novel mechanism for skeletal resistance in uremia. Kidney Int 2000, 58(2):753-761.
11. Souberbielle J.C., Boutten A., Carlier M.C., Chevenne D., Coumaros G., Lawson-Body E., et al. Inter-method variability in PTH measurement: Implication for the care of CKD patients. Kidney Int 2006, 70(2):345-350.
12. Gutierrez O.M., Farwell W.R., Kermah D., Taylor E.N. Racial differences in the relationship between vitamin D, bone mineral density, and parathyroid hormone in the National Health and Nutrition Examination Survey. Osteoporosis Int 2011, 22(6):1745-1753.
13. Ballanti P., Wedard B.M., Bonucci E. Frequency of adynamic bone disease and aluminum storage in Italian uraemic patients - retrospective analysis of 1429 iliac crest biopsies. Nephrol Dial Transplant 1996, 11(4):663-667.
14. Kazama J.J., Omori K., Yamamoto S., Ito Y., Maruyama H., Narita I., et al. Circulating osteoprotegerin affects bone metabolism in dialysis patients with mild secondary hyperparathyroidism. Ther Apher Dial 2006, 10(3):262-266.
15. Urena P., Hruby M., Ferreira A., Ang K.S., de Vernejoul M.C. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 1996, 7(3):506-512.
16. Alem A.M., Sherrard D.J., Gillen D.L., Weiss N.S., Beresford S.A., Heckbert S.R., et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000, 58(1):396-399.
17. Urena P., Bernard-Poenaru O., Ostertag A., Baudoin C., Cohen-Solal M., Cantor T., et al. Bone mineral density, biochemical markers and skeletal fractures in haemodialysis patients. Nephrol Dial Transplant 2003, 18(11):2325-2331.
18. London G.M., Marchais S.J., Guerin A.P., Boutouyrie P., Metivier F., de Vernejoul M.-C. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol 2008, 19(9):1827-1835.
19. Schoppet M., Shanahan C.M. Role for alkaline phosphatase as an inducer of vascular calcification in renal failure?. Kidney Int 2010, 73(9):989-991.
20. Urena P., Bernard-Poenaru O., Cohen-Solal M., de Vernejoul M.C. Plasma bone-specific alkaline phosphatase changes in hemodialysis patients treated by alfacalcidol. Clin Nephrol 2002, 57(4):261-273.
21. Hamano T., Oseto S., Fujii N., Ito T., Katayama M., Horio M., et al. Impact of lowering dialysate calcium concentration on serum bone turnover markers in hemodialysis patients. Bone 2005, 36(5):909-916.
22. Jorge C., Gil C., Possante M., Silva E., Andrade R., Santos N., et al. Bone alkaline phosphatase besides intact parathyroid hormone in hemodialysis patients - any advantage?. Nephron Clin Pract 2005, 101(3):c122-c127.
23. Urena P., De Vernejoul M.C. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int 1999, 55(6):2141-2156.
24. Garnero P., Delmas P.D. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 1993, 77(4):1046-1053.
25. Woitge H.W., Seibel M.J., Ziegler R. Comparison of total and bone-specific alkaline phosphatase in patients with nonskeletal disorder or metabolic bone diseases. Clin Chem 1996, 42(11):1796-1804.
26. Bunkova M., Kuleva V. Bone isoenzyme fraction of alkaline phosphatase in patients undergoing prolonged hemodialysis treatment. Vutr Boles 1978, 17(2):86-89.
27. Pierides A.M., Skillen A.W., Ellis H.A. Serum alkaline phosphatase in azotemic and hemodialysis osteodystrophy: a study of isoenzyme patterns, their correlation with bone histology, and their changes in response to treatment with 1alphaOHD3 and 1,25(OH)2D3. J Lab Clin Med 1979, 93(6):899-909.
28. Peretz A.M., Dhaene M.M., Drowart A., Kinnaert P., Vertongen F.M., Bourdoux P.P. Evolution of osteocalcin, alkaline phosphatase and parathyroid hormone after parathyroidectomy in patients receiving chronic maintenance hemodialysis. J Rheumatol 1992, 19(3):411-415.
29. Park J.C., Kovesdy C.P., Duong U., Streja E., Rambod M., Nissenson A.R., et al. Association of serum alkaline phosphatase and bone mineral density in maintenance hemodialysis patients. Hemodial Int 2010, 14(2):182-192.
30. Naik R.B., Gosling P., Price C.P. Comparative study of alkaline phosphatase isoenzymes, bone histology, and skeletal radiography in dialysis bone disease. Br Med J 1977 May 21, 1(6072):1307-1310.
31. Couttenye M.M., D'Haese P.C., Van Hoof V.O., Lemoniatou E., Goodman W., Verpooten G.A., et al. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant 1996, 11(6):1065-1072.
32. Kovesdy C.P., Ureche V., Lu J.L., Kalantar-Zadeh K. Outcome predictability of serum alkaline phosphatase in men with pre-dialysis CKD. Nephrol Dial Transplant 2010, 9(25):3003-3011.